IMW 2021 | The management of R/R multiple myeloma patients
Meral Beksac, MD, of Ankara University, Ankara, Turkey, discusses the methods used to manage disease in patients with relapsed/refractory (R/R) multiple myeloma. Dr Beksac explains that trials assessing chimeric antigen receptor T-cell (CAR-T) therapies have advanced significantly in recent years, demonstrating longer progression-free survival and higher response rates compared to trials exploring bispecific T-cell engagers (BiTEs). Dr Beksac further talks on novel targets for the treatment of multiple myeloma, in particular the use of B-cell maturation antigen (BCMA) as a therapeutic target, explaining the drawbacks of the target such as the ‘sink effect’ and how to overcomes these challenges. Additionally, Dr Beksac outlines the development of iberdomide which has shown clinical efficacy. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
Disclosures
Dr Beksac reports the following disclosures: participation in the CEPHEUS and IMROZ studies.
